Trevi Therapeutics: Navigating The 'Catch-22' Of Opioid-Based Cough Control [Seeking Alpha]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Seeking Alpha
TRVI's valuation reflects optimism, but the risk/reward profile and funding gap ahead of IPF launch warrant caution; I maintain a Hold rating. Long-term efficacy, safety, and potential controlled substance labeling are key risks for Haduvio, especially given its opioid class. IPF represents the bulk of TRVI's opportunity, while RCC faces tougher competition and more complex clinical development. AlexLMX/iStock via Getty Images Overview Trevi Therapeutics' ( TRVI ) nalbuphine ER (Haduvio) is getting some attention in chronic cough. My first look at Trevi was last November. This biotech is evaluating its kappa agonist/mu antagonist (KAMA) in late-stage trials for chronic cough in This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics (TRVI) had its price target lowered by JonesTrading from $25.00 to $24.00. They now have a "buy" rating on the stock.MarketBeat
- Trevi Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Trevi Therapeutics (TRVI) had its price target lowered by Morgan Stanley from $19.00 to $18.00. They now have an "overweight" rating on the stock.MarketBeat
- Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $19.00 price target on the stock.MarketBeat
- Trevi Therapeutics (TRVI) had its price target raised by Needham & Company LLC from $22.00 to $24.00. They now have a "buy" rating on the stock.MarketBeat
TRVI
Earnings
- 3/17/26 - Beat
TRVI
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/17/26 - Form 10-K
- 3/17/26 - Form 8-K
- TRVI's page on the SEC website